Sekhmet Pharmaventures, the PAG-backed pharmaceutical platform built around Anjan Drugs and Optimus Drugs, targets to achieve a revenue of ₹2,000 crore in three years as it repositions from volume driven API business to an integrated contract manufacturing model.The platform will invest ₹125-150 crore in capex including the addition of about 400 KL of high-compliance reactor capacity, funded from internal accruals. The company has cleared three USFDA inspections in the past year as it courts innovator clients across Europe, the US and Japan.Sekhmet, a ₹1,500 crore-plus revenue platform, is backed by PAG, CX Partners, and Samara Capital. The consortium acquired Chennai-based Anjan Drugs in October 2020 and Hyderabad-based Optimus Drugs in September 2022.Anjan anchors innovator relationships and green chemistry while Optimus brought a 200-plus scientist R&D engine and vertical integration from intermediates through finished dosage forms.Santosh Mahil, Managing Director & Chief Executive, Sekhmet said the CDMO segment today accounts for about 40 per cent of revenue and is growing at about 40-50 per cent CAGR, he said.“Qualifying a site for a commercial molecule takes five to seven years and is difficult to displace once it is done. The revenue is sticky with long order visibility and high switching cost for customer protects the relationship,” said Mahil.The 400 KL of high-compliance reactor capacity being added is expected to hit 70-75 per cent utilisation by FY27 based on existing orderbook visibility.The US Biosecure Act, signed last December has been forcing innovators to diversify away from China-linked CDMOs on a defined timeline. India’s CRDMO sector is currently estimated at around $3–3.5 billion, representing a small share of about 2–3 per cent of the global CRDMO market.Volume API businesses in India trade at 13-15 times EV/EBITDA, while integrated CDMO platforms command 35-45 times.Sekhmet frames its ₹2,000 crore goal as a 1,000-day plan with the platform compounding at roughly 35 per cent overall and CDMO running ahead of the rest.On the proposed US tariff, he said it works in favour of the company as an already-qualified supplier it can bill the US market directly rather than through India. With five plants under expansion, two land parcels near Vishakhapatnam and Chennai held for greenfield, and no IPO on the table, Sekhmet intends to fund the journey itself.Published on August 3, 2026